Biogen (BIIB) is in focus after two headline events: a first quarter 2026 earnings beat with steady revenue guidance but lower earnings expectations, and the discontinuation of a Phase 2b Parkinson’s candidate.

At a share price of US$196.0, Biogen’s 1-year total shareholder return of 51.01% contrasts with a 3-year total shareholder return that declined 34.71% and a 5-year total shareholder return that declined 31.50%. This suggests recent momentum has picked up even as longer term holders remain under water.

If you are looking beyond Biogen’s recent earnings beat and pipeline news, this is a good moment to scan for other healthcare opportunities through 37 healthcare AI stocks

With Biogen trading at US$196.0 and a mixed track record across 1, 3 and 5 years, combined with an intrinsic value estimate suggesting a large discount, you have to ask whether there is genuine upside left here or whether the market is already pricing in future growth.

Most Popular Narrative: 10.6% Undervalued

Biogen’s most followed narrative sets a fair value of about $219 per share, above the recent $196 price, and frames that gap around specific growth and margin expectations.

Demand for Biogen's Alzheimer's therapy LEQEMBI is poised for structural long-term growth, supported by a rapidly aging global population and accelerating rates of mild cognitive impairment diagnoses facilitated by breakthroughs in blood-based biomarkers and expanding diagnostic infrastructure. These factors position Biogen to capture a larger patient pool and drive sustained revenue expansion.

Want to see what earnings path supports that valuation gap? The narrative leans on measured revenue growth, firmer margins, and a future earnings multiple that sits above the broader biotech group. Curious which specific assumptions do the heavy lifting in that fair value calculation?

Result: Fair Value of $219 (UNDERVALUED)

However, that upside story can crack if key launches like LEQEMBI, SKYCLARYS or ZURZUVAE underperform, or if pricing and biosimilar pressure hit margins harder than expected.

Next Steps

With sentiment in this article leaning both optimistic and cautious, it makes sense to move quickly, review the numbers yourself, and pressure test the thesis from both sides using 2 key rewards and 1 important warning sign

Ready for more investment ideas?

Biogen may be front of mind today, but your next strong opportunity could be sitting elsewhere, so use the screener to widen your watchlist now.

• Spot potential bargains trading below their estimated worth by scanning 46 high quality undervalued stocks before the crowd catches on.
• Prioritise resilience by checking out 62 resilient stocks with low risk scores so you are not overexposed when volatility picks up.
• Get ahead of the market by searching through screener containing 22 high quality undiscovered gems before these stories become widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.